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LABORATORY INVESTIGATION
Tissue plasminogen activator therapy of glomerular thrombi in
the Shwartzman reaction
JERRY M. BERGSTEIN, with the technical assistance of MARK RILEY
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Tissue plasminogen activator therapy of glomerular thrombi in the
Shwartzman reaction. To study the effect of tissue plasminogen activa-
tor (TPA) therapy on glomerular fibrin deposition in the generalized
Shwartzman reaction, rabbits were given an intravenous injection of
TPA immediately following or three, four, or five hours after the second
injection of endotoxin. Animals were sacrificed six hours after the
second dose of endotoxin. Glomerular fibnn deposition was reduced in
animals receiving TPA four hours after the second injection of endo-
toxin and was absent in animals receiving TPA five hours after the
second dose of endotoxin. Glomerular fibrinolytic activity was reduced
following development of the generalized Shwartzman reaction but was
normal in animals that received TPA five hours after the second
injection of endotoxin. TPA did not produce a systemic fibrinolytic
state and did not prevent the decline in hematologic and coagulation
factors typical of the Shwartzman reaction, despite the elimination of
glomerular fibrin. These results suggest that TPA effectively removes
glomerular thrombi in the generalized Shwartzman reaction and infers
that TPA may be of value in the treatment of human diseases with
similar pathology, such as the hemolytic uremic syndrome.
The hemolytic uremic syndrome (HUS) is associated with
fibrin deposition within the microvasculature of the kidney [1].
As the pathogenesis of the disease is unknown, an exact
experimental model is lacking. The most comparable model of
intravascular fibrin deposition is the generalized Shwartzman
reaction (gSr) in the rabbit. Produced by two intravenous
injections of appropriate amounts of endotoxin approximately
24 hours apart [2], the gSr is characterized by marked glomer-
ular capillary fibrin deposition [31, resulting in renal cortical
necrosis.
That inhibition of fibrinolysis may play a role in the genesis of
the gSr was suggested by the observations that epsilon amino-
caproic acid, a potent inhibitor of fibrinolysis, could substitute
for either the preparatory [4] or provoking [5] injection of
endotoxin. Indeed, the unique sensitivity of the rabbit to
glomerular fibrin deposition and the gSr in comparison to other
species may be related to a low level of renal cortical plasmin-
ogen activator [6]. Rabbit glomerular fibrinolytic activity is
transiently diminished after the preparatory injection of endo-
toxin and persistently diminished following the development of
the gSr [7]. This loss of glomerular fibrinolysis is associated
with the presence of a circulating inhibitor of glomerular
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fibrinolytic activity that may derive, at least in part, from
platelets [8]. Interestingly, an inhibitor of glomerular fibrino-
lysis has also been found in the plasma of children with HUS
[9].
Because glomerular fibrinolytic activity appears to be inade-
quate to remove glomerular fibrin deposits in the gSr and,
perhaps, in certain patients with HUS, the administration of
fibrinolytic agents might augment endogenous fibrinolytic
mechanisms [10] to remove glomerular fibrin deposits and
prevent the development of cortical necrosis. A crude prepara-
tion of streptokinase given after the provoking injection of
endotoxin has been shown to reduce glomerular fibrin deposi-
tion in the gSr [11—13]. The purified plasminogen activators
streptokinase [14, 151 and urokinase [16] have been adminis-
tered to a few children with HUS. However, the absence of
predictors of a poor outcome, lack of controlled clinical trials,
and the significant risk of serious bleeding due to induction of a
systemic fibrinolytic state have constrained most investigators
from further use of these agents.
In comparison to streptokinase and urokinase, tissue plasmin-
ogen actiyator (TPA) is unique in that it stimulates clot lysis
without inducing a systemic fibrinolytic state [17]. Streptoki-
nase and urokinase convert plasminogen to plasmin in the
blood. Circulating plasmin, a proteolytic enzyme with low
substrate specificity, degrades and depletes coagulation factors
and fibrinogen and consumes circulating antiplasmins, resulting
in a systemic fibrinolytic state and the potential for serious
hemorrhage. TPA, on the other hand, has a strong affinity for
fibrin but little affinity for circulating plasminogen [18]. In a clot,
TPA forms a complex with fibrin that does have a strong affinity
for plasminogen bound to the clot. Plasminogen is converted to
plasmin within the clot, resulting in clot lysis. Small amounts of
plasmin formed in the blood or leaking from clots into the
circulation are neutralized by antiplasmins, avoiding the devel-
opment of a systemic fibrinolytic state [19].
Until recently, TPA was obtainable only in small amounts by
purification from the culture medium of a human melanoma cell
line. Experiments in animals using melanoma-derived TPA
indicated that TPA is more potent and specific than urokinase
[201. Human TPA is now being produced in larger quantities
using recombinant DNA technology [211. This product, whose
biological properties seem virtually identical to melanoma-
derived TPA [22], has been used successfully in the treatment
of coronary artery [23], peripheral artery and bypass graft
thrombosis [241, and pulmonary embolism [25]. The purpose of
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this study was to investigate the value of recombinant TPA in
the treatment of glomerular capillary fibrin deposition in the gSr
as a prelude to its possible use in human microvascular disease.
Methods
Bovine fibrinogen was obtained from Miles Laboratories
(Elkhart, Indiana, USA), Na'251 from Amersham (Arlington
Heights, Illinois, USA), Triton X-100 from Sigma Chemical
Company (St. Louis, Missouri, USA), lysine-Sepharose 4B
from Pharmacia Fine Chemicals (Piscataway, New Jersey,
USA), plasminogen-free human thrombin from Dr. John W.
Fenton II, New York State Department of Health, Albany,
New York, USA, 24-well polystyrene tissue culture cluster
plates from Costar (Cambridge, Massachusetts, USA), and
endotoxin (lipopolysaccharide B from Escherichia coli 026:B6)
from Difco Laboratories (Detroit, Michigan, USA). TPA was
from Genentech, Inc., South San Francisco, California, USA.
Purified urokinase was from Dr. Karl Eurenius, National Heart,
Lung, and Blood Institute, National Institutes of Health.
Human plasminogen was prepared by the method of Deutsch
and Mertz [261 and was treated with phenyl-methyl-sulfonyl-
fluoride to remove traces of plasmin activity. Platelet and
leukocyte counts were performed as previously described [81.
Plasma levels of coagulation factors V, VIII, and fibrinogen
were determined by the Coagulation Laboratory of the Indiana
University School of Medicine using methods and reagents
obtained from Dade Division, American Hospital Supply Cor-
poration (Miami, Florida, USA). Factor V and VIII levels were
expressed as the percent of the mean value measured in 12
normal rabbits (Group 6 below).
Histologic techniques
Renal cortex from the left kidney was obtained at open
biopsy or immediately after sacrifice. For light microscopy, part
of the tissue specimen was placed into buffered formalin (pH
7.4), sectioned at 4 j., and stained with hematoxylin-eosin.
Glomerular thrombi were recognized by the accumulation of
dark eosinophilic fibrillar or amorphous material within the
glomerular capillaries. The remainder of the tissue was cut into
2 x 4 mm portions, snap-frozen in isopentane precooled in
liquid nitrogen, and stored at —70°C until studied. Part of the
frozen tissue was sectioned at 4 iand stained for immunoflu-
orescence microscopy using fluorescein-conjugated sheep anti-
serum specific for rabbit fibrinogen (Cooper Biomedical, Mal-
vern, Pennsylvania, USA). The remainder of the frozen tissue
was utilized to measure glomerular fibrinolytic activity.
Fifty glomeruli were evaluated by light and immunofluores-
cence microscopy. The gSr was defined as the presence of fibrin
thrombi in 100% of glomeruli by both light and immunofluores-
cence microscopy. Absence of the gSr was indicated by the
complete absence of glomerular fibrin deposits by both his-
tologic techniques.
Measurement of glomerular fibrinolytic activity
Glomerular fibrinolytic activity was measured using a modi-
fication of the 1251-labeled fibrin film technique as previously
described [271. The fibrinolytic activity of the glomerular ex-
tracts was determined by measuring the radioactivity released
after an 18 hour incubation of the reaction mixture, which
contained the extract to be tested in 0.5 ml of 0.2 M phosphate-
Table 1. The effect of TPA on glomerul ar fibrin deposition in the gSr
No. of animals
No. of with glomerular
Group Protocol° animals fibrin
6 hr
I E1—*E2----- Sac 7 6
2 E1 — E2 + TPA— Sac
3 E—E2.-* TPA— Sac
7
6
6
4
4 TPA- Sac
5 E1 — E2- TPA-- Sac
6
8
2
0b
° E1 and E2 indicate the preparatory and provoking injections of
endotoxin; TPA indicates tissue plasminogen activator; Sac indicates
sacrificed.b p = 0.001 in comparison to Group 1.
buffered saline, pH 7.4 (PBS), and 10 d (4.0 g) of human
plasminogen. After incubation in a moist chamber at 37°C, the
radioactivity released into 0.3 ml of the reaction mixture was
counted in a gamma spectrometer. All plates contain controls
for background radioactivity release and non-specific proteo-
lytic activity by including wells containing PBS with and
without plasminogen and urokinase and glomerular extract
without plasminogen.
Individual glomeruli were isolated as previously described
[271. Two sets of 15 glomeruli from each tissue specimen were
separately extracted for 60 minutes at 37°C in 0.5 ml of PBS
containing 0.0 1% Triton X-lOO. After centrifugation at 5000 x g
for 30 minutes, the reaction mixture was studied in the 1251
fibrin films. For each kidney studied, the activator activity was
initially expressed as the average value of the percent release of
total radioactivity in the wells of the two sets of glomeruli per
p.g of protein [281 as long as the variation between the sets was
less than 10%. If this variation exceeded 10%, then the tissue
assay was repeated. As a control, a standard urokinase curve
was run on each plate. The final result of each tissue analysis
was then expressed as the equivalent IU of urokinase per g of
protein.
Experimental design
Fifty, 2-kg albino rabbits were studied in seven groups.
Animals in Groups 1 to 5 received two ear vein injections of
endotoxin (0.25 mg/kg in 2 ml of sterile water) 24 hours apart
(Table 1). Immediately after the second injection of endotoxin,
animals in Group 2 were given an ear vein injection of 0.5 mgI
kg TPA in 1 ml of sterile water (a dose shown to produce
effective fibrinolysis in rabbits [29, 30]), half as bolus and half as
an infusion over 15 minutes. Animals in Groups 3, 4, and 5
received similar injections of TPA beginning three, four, and
five hours after the second dose of endotoxin. Animals were
sacrificed six hours after the second injection of endotoxin.
Blood samples (4 ml of blood in a polypropylene tube contain-
ing 0.44 ml of 3.8% sodium citrate) were obtained prior to each
injection of endotoxin and just prior to sacrifice. The plasma
was separated by centrifugation at 2000 x g for 10 minutes and
preserved at —70°C until studied,
Group 6 contained 12 normal rabbits who underwent blood
sampling and kidney biopsy to establish control physiologic
values.
Group 7 included four normal animals given a single ear vein
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Table 2. Glomerular fibrinolytic activity
Group
Activity level
x 1O IV urokinasel
p.g protein
Comparison
to group 6
P value
1
2
3
4
5
6 (normals)
65.6 1l.8
81.3 31.5
70.3 3.5
78.0 15.8
104.7 12.9
110.8 32.42
0.001
0.048
0.001
0.048
0.300
—
a Mean SD
injection of TPA (0.5 mg/kg) as above. Blood and kidney
samples were obtained prior to and 15, 30, and 60 minutes after
the injection of TPA.
Statistics
The effect of TPA on glomerular fibrin deposition was ana-
lyzed using Fisher's exact test. Multiple comparisons were
performed by one-way or two-way analysis of variance using
the method of unweighted means for unequal group size. In
analyzing the changes in the hematologic parameters, individual
comparison t-tests were carried out after the analysis of the
variance to compare the changes at the different time intervals
in Group 1 with the corresponding changes in each of the other
groups [31].
Results
Six of seven animals given two injections of endotoxin
(Group 1) developed the gSr, characterized by glomerular fibrin
deposition in 100% of glomeruli by both light and immunofluo-
rescence microscopy (Table 1). One rabbit showed no evidence
of glomerular fibrin by either technique. Similarly, six of seven
animals given TPA immediately after the second injection of
endotoxin (Group 2) developed the gSr. Although four of six
animals given TPA three hours after the second dose of
endotoxin developed the gSr (Group 3), only two of six animals
developed the gSr when TPA was given four hours after the
second injection of endotoxin (Group 4). When TPA was given
five hours after the second dose of endotoxin (Group 5),
glomerular fibrin deposition was absent (P = 0.001 in compar-
ison to Group 1) by light and immunofluorescence microscopy
in tissue from all eight animals studied (Table 1).
In comparison to normal rabbits (Group 6), animals receiving
two doses of endotoxin (Group 1) had significantly (P = 0.001)
less glomerular fibrinolytic activity when sacrificed six hours
after the second injection of endotoxin (Table 2). Glomerular
fibrinolytic activity was also reduced in animals receiving TPA
in conjunction with the second dose of endotoxin (Group 2) and
in animals receiving TPA three (Group 3) and four (Group 4)
hours after the second dose of endotoxin (Table 2). However,
glomerular fibnnolytic activator activity was normal in animals
(Group 5) receiving TPA five hours after the second dose of
endotoxin (I hr prior to sacrifice).
In comparison to animals receiving two injections of endo-
toxin without TPA (Group 1), there were no significant (P >
0.05) differences (Fig. 1) in the declines in the platelet and white
blood cell counts or the factor V and VIII levels in animals
receiving endotoxin and TPA at any time interval following the
second injection of endotoxin (Groups 2 to 5). A significant (P
<0.01) decline in fibrinogen was noted in animals given TPA 3
(Group 3) and five hours (Group 5) after the second injection of
endotoxin (Fig. 1) in comparison to animals (Group 1) that
received endotoxin but not TPA. Despite the significant reduc-
tions in fibrinogen levels in Groups 3 and 5 in comparison to
Group 1, the actual fibrinogen values in all three groups
remained at or above their pre-experiment levels,
In the four normal rabbits given TPA (Group 7), glomerular
fibrin deposits were absent and no significant (P > 0.05)
changes were detected in the platelet, white blood cell, fibrin-
ogen, and glomerular fibrinolysis levels up to one hour after
administration of TPA (Table 3).
Discussion
Our results suggest that, in the gSr, glomerular fibrin deposits
are removed by TPA. These deposits form two to four hours
after the provoking injection of endotoxin [2, 32]. Because TPA
is relatively inactive in the absence of fibrin [17], it is not
surprising that TPA showed no effect when given within three
hours (Groups 2 and 3) after the second injection of endotoxin.
However, when given four hours after the second injection of
endotoxin, only two of six animals developed the gSr. When
TPA was given five hours after the provoking injection of
endotoxin, a time at which glomerular fibrin deposition is
extensive [32], no fibrin deposits were subsequently detected in
animals (Group 5) sacrificed one hour later.
Using a new technique to quantitate glomerular fibrinolytic
activity, we have confirmed that this activity is reduced follow-
ing development of the gSr [7]. The effective fibrinolytic activity
of the glomerulus derives from the activity of elaborated
plasminogen activators [27] as potentially modified by the levels
of plasminogen activator inhibitors and antiplasmins. We have
previously shown that a circulating inhibitor of glomerular
fibrinolysis is released into the circulation after the first and the
second injection of endotoxin, and that this inhibitor is present
at high levels six hours after the second injection of endotoxin
when glomerular fibrin deposition is massive [8]. In this study,
we suggest that TPA is able to overcome the effect of this
inhibitor and dissolve glomerular fibrin deposits. That TPA,
apart from its fibrinolytic activity, did not effectively neutralize
the inhibitor of glomerular fibrinolysis is suggested by the low
levels of glomerular fibrinolytic activity in Groups 2 and 3. In
these groups, glomerular fibrin which might have bound TPA
was presumably absent when TPA was administered, thus
allowing injected TPA to interact with the circulating inhibitor.
Yet glomerular fibrinolytic activity in these groups was similar
to animals who had not received TPA (Group 1).
Glomerular fibrinolytic activity was normal (and glomerular
fibrin was absent) in animals given TPA five hours after the
second injection of endotoxin (Group 5). Because the half-life of
TPA in the circulation of rabbits is approximately 10 minutes
[30], it is unlikely that the normal level of glomerular fibrinolytic
activity found in Group 5 rabbits is mediated by administered
TPA, especially in the absence of fibrin to bind TPA [33].
Rather, it seems likely that the administered TPA dissolved the
initial fibrin deposits, preventing depletion of endogenous fibri-
nolytic mechanisms, and that persistence of endogenous fi-
brinolysis prevented subsequent fibrin deposition. Persistence
of glomerular fibrinolytic activity has been shown to play a
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Table 3. Effect of TPA on 4 normal rabbits (Group 7)
Minutes after injection of TPA
0 15 30 60
Platelets No.1mm3 217,000 23,600" 221,000 7000 200,000 15,000 221,000 10,600
White blood cells No/mm3 7800 1800 8500 1700 7250 2600 8125 700
Fibrinogen mgldl 257 34 282 58 377 62 280 43
Glomerular fibrinolysis" 104 40 95.1 15 91.0 12 98.0 14
Renal cortical tissue from all animals was normal by immunofluorescence microscopyb Mean SD
x 10-6 LU urokinaseItg protein
central role in the removal of glomerular fibrin deposits and the
prevention of cortical necrosis in a rat model of the gSr [34].
Platelet, white blood cell, and fibrinogen levels and glomer-
ular fibrinolytic activity remained normal up to one hour after
the administration of TPA to normal rabbits, confirming the
lack of development of a systemic fibrinolytic state at the dose
of TPA administered. Interestingly, despite its beneficial effect
on the kidneys, TPA failed to prevent the hematologic and
coagulation abnormalities of the gSr. Heparin, which prevents
glomerular fibrin deposition [35, 36] in the gSr, also fails to
prevent the hematologic and coagulation abnormalities of the
reaction. This suggests that both TPA and heparin act at the
level of fibrin formation and deposition rather than on the
primary pathogenic mechanisms of the gSr which presumably
occur earlier in the reaction.
The results of this study suggest that TPA is effective in
dissolving thrombi within the microvasculature of the kidneys
and infer that TPA may be of value in human diseases, such as
HUS, with similar pathologic alterations.
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